Taysha Gene Therapies plans to release third quarter 2026 earnings and corporate update

Taysha Gene Therapies plans to release third quarter 2026 earnings and corporate update
Taysha Gene Therapies Q3 2026 earnings

Taysha Gene Therapies will announce its third quarter 2026 earnings and provide a corporate update next week.

The company is inviting stakeholders to visit its website for more information about the upcoming release and any additional details related to its business performance.

In recent months, Taysha Gene Therapies has highlighted clinical progress on its TSHA-102 Rett syndrome program during a key neurology meeting, as reported here. The company also discussed advancements in its TSHA-102 gene therapy at the CNSAM event with the neurology community, according to a previous update. These updates follow Taysha’s ongoing communication with stakeholders about its product pipeline and clinical development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.